Swissmedic approves IFINWIL® (eflornithine) for children diagnosed with high-risk neuroblastoma (HRNB)

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NORGINE-Swissmedic

More Like This

PR Newswire associated0

Norgine welcomes TGA registration in Australia of IFINWIL® (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

PR Newswire associated0

Norgine B.V. submits Marketing Authorisation Application via Project Orbis for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

PR Newswire associated0

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

PR Newswire associated0

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

PR Newswire associated0

Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome

PR Newswire associated0

European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Hansa Biopharma Submits BLA to FDA for Imlifidase in desensitization for Kidney Transplantation